Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer
Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer
复制标题
DOI：
10.1007/s10147-012-0503-8
复制
发表时间：
2014-02-01
影响因子：
3.3
通讯作者：
Date, Hiroshi
中科院分区：
文献类型：
--
作者：
Sakamoto, Jin;Sonobe, Makoto;Date, Hiroshi
背景非小细胞肺癌（NSCLC）术后复发降低了患者的预期寿命。在这项回顾性研究中，我们调查了手术切除的非小细胞肺癌（NSCLC）术后脑转移患者的预后因素。方法我们对2004年4月至2009年2月期间接受NSCLC切除术的患者进行了回顾性图表分析，发现65例患者在2010年3月之前发生了术后脑转移。我们回顾这些患者的临床病理资料，治疗和治疗反应，和总survival.Results脑转移瘤诊断后的5年生存率为15.4%。诊断为脑转移后患者的显著有利预后因素包括女性、腺癌、少量（1-3例）脑转移、诊断为脑转移时无颅外转移、放射治疗（全脑放射和/或立体定向放射）和局部治疗[立体定向放射和/或外科手术（开颅术）]。此外，在仅以脑转移为术后首次复发的患者中，有利的阳性预后因素包括少量（1-3个）脑转移、辅助化疗、化疗（包括辅助化疗和其他化疗，但不包括表皮生长因子受体酪氨酸激酶抑制剂），结论脑转移瘤术后的上述临床特征和治疗有助于患者的生存期待
Background Postoperative recurrence in non-small cell lung cancer (NSCLC) reduces the life expectancy of patients. In this retrospective study, we investigated the prognostic factors in patients with postoperative brain metastases from surgical resected non-small cell lung cancer (NSCLC).Methods We conducted a retrospective chart review of patients who had undergone resection for NSCLC between April 2004 and February 2009 and found 65 had experienced postoperative brain metastases by March 2010. We reviewed these patients for clinicopathological information, treatments and responses to treatment, and overall survival.Results The 5-year survival rate after the diagnosis of brain metastases was 15.4 %. Significantly favorable prognostic factors for patients after a diagnosis of brain metastases included female gender, adenocarcinoma, a small number (1-3) of brain metastases, no extracranial metastasis at the diagnosis of brain metastases, radiation treatment (whole-brain radiation and/or stereotactic irradiation), and local treatment [stereotactic irradiation and/or surgical operation (craniotomy)]. Furthermore, in patients with only brain metastases as the postoperative initial recurrence, the favorable positive prognostic factors included a small number (1-3) of brain metastases, adjuvant chemotherapy, chemotherapy (including adjuvant and other chemotherapy and excluding epidermal growth factor receptor-tyrosine kinase inhibitors), and local treatment.Conclusions Our study found that the foregoing clinical characteristics in postoperative brain metastases and the administration of treatment contributed to patient life expectancy.